BEIGF:OTCMKTS
BeOne Medicines
21,95 $
0,00%
(0,00) 1D
9 мау., 12:49:46 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEIGF...
Mkt. cap
42,86 млрд
Avg. vol.
0,00
Volume
0,00
52-wk high
24,92 $
52-wk low
21,95 $
Beta
0,84
Shares outstanding
1,43 млрд
No. of employees
12 мың
Mkt. cap
42,86 млрд
Avg. vol.
0,00
Volume
0,00
52-wk high
24,92 $
52-wk low
21,95 $
Beta
0,84
Shares outstanding
1,43 млрд
No. of employees
12 мың
News stories
From web sources and news partners
GlobeNewswire
·
41 минут бұрын
FBS Global Regains Compliance with Nasdaq Minimum Bid Price Requirement
Stock Titan
·
46 минут бұрын
After 30 business days below $1, AGM Group (Nasdaq: AGMH) gets time to regain compliance.
Seeking Alpha
·
1 сағат бұрын
Three things to look out for on Wednesday
Investor's Business Daily
·
37 минут бұрын
Dow Jones Futures: Stock Market Holds Up As Meta, AMD Lead Buys; ASML, CPI Inflation Due
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 мың
Founded2010 ж. 28 қаз.
Headquarters-
Sector-
Websitebeonemedicines.com